Home / Drug development / ADME-Tox / In vivo DMPK
In vivo DMPK
We run in vivo DMPK studies that show how your compound absorbs, distributes and eliminates to deliver the data you need to de-risk decisions and advance confidently toward IND.
Conducted at our AAALAC-accredited facilities, these studies stand alone or integrate seamlessly with in vitro ADME-Tox programs.
Symeres supports in vivo DMPK with openness, agility and scientific depth across services including:
- Pharmacokinetic profiling
- Single and repeated dosing via multiple administration routes, including surgical routes
- Single compound or cassette dosing approaches
- Tissue distribution and CNS exposure studies
- Biomarker analysis to support the evaluation and characterization of pharmacodynamic effects
- Excretion and mass balance studies with cold or radiolabelled compounds
- Bioanalysis by LC-MS/MS or UPLC-HR/MS, ligand binding assays, qPCR, radioactivity detection (14C, 3H)
- In vivo metabolite identification and profiling to support safety metabolism assessment and MIST analysis
Related services
ADME services delivered by Admescope
All ADME services, including in vitro ADME, in vivo PK screening, ADME-Tox in vivo DMPK are performed by Admescope (a Symeres company).
DMPK mastery
Pharmacokinetic expertise
In-depth DMPK interpretation for exposure, clearance, and distribution analysis across species.
Regulatory alignment
Study packages from discovery to IND designed to meet regulatory data requirements and avoid rework – keeping your timelines intact.
Flexible study design
Run independently or integrated with in vitro ADME-tox for consistent data and faster decisions.
Integrated ADME-Tox services
Our in vivo DMPK and in vitro ADME-Tox capabilities work together to give you a clear view of exposure, safety, and metabolism.
Integrated data across studies reduces uncertainty and helps you prioritize safer candidates and progress faster.
What do our partners say?
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
Your discovery and development partner
We support programs from target exploration through IND, combining assay biology, ADME-Tox, medicinal chemistry, and CMC development.
Our connected teams in Europe and North America share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous
Resources we think you'll love
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our in vivo DMPK experts
See how we can support the discovery and development of your next breakthrough.